Tango Therapeutics
Investors
Join Us
Contact
Science
Approach
Platform
Publications + Posters
Pipeline
Programs
PRMT5
Clinical Trials
Leadership
Home
Science
▼
Approach
Platform
Publications + Posters
Pipeline
Programs
▼
PRMT5
Clinical Trials
Leadership
Join Us
Investors
▼
Overview
News & Events
▼
News Releases
Events & Presentations
Governance
▼
Overview
Executive Leadership
Board of Directors
Committee Composition
Stock Information
▼
Stock Quote & Chart
Financials
▼
SEC Filings
Resources
▼
Investor FAQs
Email Alerts
Contact IR
Contact
Publications + Posters
|
EORTC-NCI-AACR
October 2025
Hit finding and assay enablement for MGAT1, a novel glycosyltransferase involved in cancer cell immune evasion
Katarzyna B. Handing, et al.
|
EORTC-NCI-AACR
October 2025
APEX2 is a synthetic lethal target for RNASEH2B-deleted or BRCA-mutant tumors
Antoine Simoneau, et al.
|
EORTC-NCI-AACR
October 2025
TNG961: A selective oral molecular glue degrader of HBS1L inducing tumor regression in naïve and PRMT5i-refractory FOCAD-deleted models
Katherine Lazarides, et al.
|
AACR Cancer Research
September 2025
TNG260 is a Small-Molecule CoREST Inhibitor that Sensitizes STK11-Mutant Tumors to Anti-PD-1 Immunotherapy
Leanne G. Ahronian, et al.
|
AACR Clinical Cancer Research
June 2025
MTA-Cooperative PRMT5 Inhibitors are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models
Xiaochun Zhang, et al.
Learn more about our drug discovery programs and explore our pipeline.